Abstract:Nirmatrelvir is the antiviral component of nirmatrelvir/ritonavir, the first US Food and Drug Administration–approved oral antiviral for treatment of COVID-19 in adults. The widespread use of nirmatrelvir, in the absence of similarly effective alternatives, raises concerns about the emergence of nirmatrelvir-resistant variants. Scientists have identified a number of SARS-CoV-2 mutations that confer nirmatrelvir resistance in cell-based assays, 1 but they were rarely found in clinical specimens. 2 Elsewhere in JAMA Network Open , Tamura et al 3 give a timely assessment of nirmatrelvir-resistant variants in clinical settings. Using a highly sensitive next-generation sequencing approach, the researchers analyzed samples from a cohort of individuals with acute COVID-19 who were either treated with nirmatrelvir or left untreated. This study provides evidence that the risk of clinically significant resistance is currently low. While nirmatrelvir resistance mutations were detected more frequently in treated individuals, these mutations were mostly rare, appeared transiently, and did not appear to pose a substantial risk of virologic rebound. The findings are in line with other retrospective studies showing similar low frequency of nirmatrelvir-resistant variants, 2 suggesting that nirmatrelvir is still effective against most circulating variants. Although this study provides generally reassuring evidence, it does raise some concerns for immunocompromised populations. The researchers found that 23% immunocompromised patients with COVID-19 (5 of 22) harbored nirmatrelvir-resistant variants during or after nirmatrelvir treatment, compared with only 7% in immunocompetent patients (4 of 57). This finding, together with others, 4 pinpoints immunocompromised populations as a potential source of nirmatrelvir-resistant variants. Immunocompromised individuals appear to be at higher risk of developing SARS-CoV-2 mutations. A competent immune system usually clears SARS-CoV-2 infection within days after symptom onset, limiting opportunities for mutations to arise. However, prolonged or recurrent infections in immunocompromised individuals create a breeding ground for mutations, 4 resulting in increased viral genetic diversity, ie, a larger pool for drug selection. Nirmatrelvir, as other potent and selective antivirals, requires only a short treatment course of 5 days, 5 limiting the window of opportunity for a nirmatrelvir-resistant variant to become dominant. However, in immunocompromised individuals, nirmatrelvir treatment often extends beyond the standard 5 days due to their delayed viral clearance. 4 This prolonged treatment creates a longer window of selection pressure, potentially facilitating nirmatrelvir-resistant variants to gain dominance. This concern is underscored by the case reported by Tamura et al, 3 in which a nirmatrelvir-resistant variant in an immunocompromised patient treated with nirmatrelvir for 6 days reached 31% dominance just 2 days after an undetected test. Such rapid evolution of the viral population would warrant close monitoring of immunocompromised individuals receiving prolonged nirmatrelvir treatment. Nirmatrelvir is not authorized for prevention of COVID-19, 5 which helps limit the spread of nirmatrelvir-resistant variants. Under this guidance, a nirmatrelvir-resistant variant would no longer have selection advantage after spreading into a new host. Additionally, most nirmatrelvir-resistant mutations weaken viral fitness, making nirmatrelvir-resistant variants less competitive. 1 This was observed in the study by Tamura et al, 3 in which resistant variants were quickly outcompeted by nonresistant variants after cessation of nirmatrelvir treatment. However, influenza A viruses with oseltamivir resistance mutations (H274Y) demonstrate that additional permissive mutations can restore viral fitness, 6 and there is already a report 7 of SARS-CoV-2 variants acquiring both nirmatrelvir resistance and high fitness through a combination of mutations in cell culture. If there is epistasis (interactions between mutations) such that multiple mutations are required for both drug resistance and viral fitness, the prolonged infections in immunocompromised hosts would allow these mutations to accumulate sequentially. This could enable the virus to make evolutionary jumps toward dominant drug–resistant variants. These observations highlight the hidden risk of nirmatrelvir resistance and again stress the importance of proactive viral genomics surveillance in immunocompromised populations. Nirmatrelvir's recent arrival on the scene compared with other antivirals highlights a constant challenge: the inevitable emergence of drug resistance. This sets the stage for an ongoing arms race between drug development and pathogen -Abstract Truncated-

A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral rebound

Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?

A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System

Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19

Real-World Effectiveness of Nirmatrelvir/Ritonavir and Dexamethasone among Hospitalized Patients with COVID-19: A Prospective Cohort Study.

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations

Structural basis for Nirmatrelvir in vitro efficacy against SARS-CoV-2 variants

Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study

Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19

Advances and Challenges in Using Nirmatrelvir and Its Derivatives Against SARS-CoV-2 Infection.

Association of nirmatrelvir/ritonavir treatment on upper respiratory SARS-CoV-2 RT-PCR negative conversion rates among high-risk patients with COVID-19

Emerging SARS-CoV-2 Resistance After Antiviral Treatment

COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina

Analysis of Nirmatrelvir Entry into Pulmonary Lining Fluid in Patients with COVID‐19: A Unique Perspective to Explore and Understand the Target Plasma Concentration of 292 ng/mL in Antiviral Activity

Nirmatrelvir–Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing

SARS-CoV-2 Nirmatrelvir Resistance—A Concern for Immunocompromised Populations?

Physiologically‐based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID‐19

Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system